Small molecule MYC inhibitor conjugated to integrin-targeted nanoparticles extends survival in a mouse model of disseminated multiple myeloma

Molecular Cancer Therapeutics

Volumn 14, Issue 6, 2015, Pages 1286-1294

  Soodgupta, Deepti ^a   Pan, Dipanjan ^b   Cui, Grace ^a   Senpan, Angana ^a   Yang, Xiaoxia ^a   Lu, Lan ^a   Weilbaecher, Katherine N ^a   Prochownik, Edward V ^c   Lanza, Gregory M ^a   Tomasson, Michael H ^a  

^a WASHINGTON UNIVERSITY   (United States)

^b University of Illinois at Urbana Champaign   (United States)

^c UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA4 INTEGRIN; ANTINEOPLASTIC AGENT; INTEGRIN; MYC PROTEIN; NANOPARTICLE; PRODRUG; SMALL MOLECULE MYC INHIBITOR; UNCLASSIFIED DRUG; VERY LATE ACTIVATION ANTIGEN 4; VITRONECTIN RECEPTOR; BASIC HELIX LOOP HELIX LEUCINE ZIPPER TRANSCRIPTION FACTOR; MAX PROTEIN, HUMAN; MOLECULAR LIBRARY;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER SURVIVAL; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; DIMERIZATION; DRUG BINDING; DRUG DELIVERY SYSTEM; DRUG EFFICACY; HUMAN; HUMAN CELL; MOLECULARLY TARGETED THERAPY; MOUSE; MULTIPLE MYELOMA; MULTIPLE MYELOMA CELL LINE; NANOMEDICINE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR VOLUME; U266 CELL LINE; ANIMAL; ANTAGONISTS AND INHIBITORS; CELL SURVIVAL; CHEMISTRY; DISEASE MODEL; DOSE RESPONSE; DRUG EFFECTS; METABOLISM; MOLECULAR LIBRARY; PATHOLOGY; PHARMACOLOGY; PROTEIN MULTIMERIZATION; SURVIVAL ANALYSIS; TUMOR CELL LINE; WESTERN BLOTTING;

ANIMALS; APOPTOSIS; BASIC HELIX-LOOP-HELIX LEUCINE ZIPPER TRANSCRIPTION FACTORS; BLOTTING, WESTERN; CELL LINE, TUMOR; CELL SURVIVAL; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; INTEGRIN ALPHA4BETA1; INTEGRIN ALPHAVBETA3; MICE; MULTIPLE MYELOMA; NANOPARTICLES; PRODRUGS; PROTEIN MULTIMERIZATION; PROTO-ONCOGENE PROTEINS C-MYC; SMALL MOLECULE LIBRARIES; SURVIVAL ANALYSIS; TUMOR BURDEN;

EID: 84942113043     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-14-0774-T     Document Type: Article

References (37)

1. Edwards BK, Ward E, Kohler BA, Eheman C, Zauber AG, Anderson RN, et al. Annual report to the nation on the status of cancer, 1975-2006, featuring colorectal cancer trends and impact of interventions (Risk Factors, Screening, and Treatment) to reduce future rates. Cancer 2010;116:544-73.
2. Kuehl WM, Bergsagel PL. Myc addiction: a potential therapeutic target in Mm. Blood 2012;120:2351-2.
3. Anguiano A, Tuchman SA, Acharya C, Salter K, Gasparetto C, Zhan F, et al. Gene expression profiles of tumor biology provide a novel approach to prognosis and may guide the selection of therapeutic targets in multiple myeloma. J Clin Oncol 2009;27:4197-203.
4. Chng WJ, Huang GF, Chung TH, Ng SB, Gonzalez-Paz N, Troska-Price T, et al. Clinical and biological implications of MYC activation: a common difference between MGUS and newly diagnosed multiple myeloma. Leukemia 2011;25:1026-35.
5. Dib A, Gabrea A, Glebov OK, Bergsagel PL, Kuehl WM. Characterization of MYC translocations in multiple myeloma cell lines. J Natl Cancer Inst Monogr 2008:25-31.
6. Avet-Loiseau H. Role of genetics in prognostication inmyeloma. Best Pract Res Clin Haematol 2007;20:625-35.
7. Chen JP, Lin C, Xu CP, Zhang XY, Fu M, Deng YP, et al. Molecular therapy with recombinant antisense c-myc adenovirus forhuman gastric carcinoma cells in vitro and in vivo. J Gastroenterol Hepatol 2001;16:22-8.
8. Lewis DL, Hagstrom JE, Loomis AG, Wolff JA, Herweijer H. efficient delivery of sirna for inhibition of gene expression in postnatal mice. Nat Genet 2002;32:107-8.
9. Berg T, Cohen SB, Desharnais J, Sonderegger C, Maslyar DJ, Goldberg J, et al. Small-molecule antagonists of Myc/Max dimerization inhibit Mycinduced transformation of chicken embryo fibroblasts. Proc Natl Acad Sci U S A 2002;99:3830-5.
10. Murre C, McCaw PS, Vaessin H, Caudy M, Jan LY, Jan YN, et al. interactions between heterologous helix-loop-helix proteins generate complexes that bind specifically to a common DNA sequence. Cell 1989;58:537-44.
11. Amati B, Littlewood TD, Evan GI, Land H. The c-Myc protein induces cell cycle progression and apoptosis through dimerization with Max. EMBO J 1993;12:5083-7.
12. Freytag SO, Dang CV, Lee WM. Definition of the activities and properties of c-myc required to inhibit cell differentiation. Cell Growth Differ 1990;1:339-43.
13. Smith MJ, Charron-Prochownik DC, Prochownik EV. The leucine zipper of c-Myc is required for full inhibition of erythroleukemia differentiation. Mol Cell Biol 1990;10:5333-9.
14. Hermeking H. The Myc oncogene as a cancer drug target. Curr Cancer Drug Targets 2003;3:163-75.
15. Prochownik EV. c-Myc as a therapeutic target in cancer. Expert Rev Anticancer Ther 2004;4:289-302.
16. Darnell JE Jr. Transcription factors as targets for cancer therapy. Nat Rev Cancer 2002;2:740-9.
17. Gibbs JB. Mechanism-based target identification and drug discovery in cancer research. Science 2000;287:1969-73.
18. Kiessling A, Sperl B, Hollis A, Eick D, Berg T. Selective inhibition of c-Myc/Max dimerization and DNA binding by small molecules. Chem Biol 2006;13:745-51.
19. Bagnasco L, Tortolina L, Biasotti B, Castagnino N, Ponassi R, Tomati V, et al. Inhibition of a protein-protein interaction between INI1 and c-Myc by small peptidomimetic molecules inspired by Helix-1 of c-Myc: identification of a new target of potential antineoplastic interest. FASEB J 2007;21:1256-63.
20. Yin X, Giap C, Lazo JS, Prochownik EV. Low molecular weight inhibitors of Myc-Max interaction and function. Oncogene 2003;22:6151-9.
21. Clausen DM, Guo J, Parise RA, Beumer JH, Egorin MJ, Lazo JS, et al. In vitro cytotoxicity and in vivo efficacy, pharmacokinetics, and metabolism of 10074-G5, a novel small-molecule inhibitor of c-Myc/Max dimerization. J Pharmacol Exp Ther 2010;335:715-27.
22. Lanza GM, Yu X, Winter PM, Abendschein DR, Karukstis KK, Scott MJ, et al. Targeted antiproliferative drug delivery to vascular smooth muscle cells with a magnetic resonance imaging nanoparticle contrast agent: implications for rational therapy of restenosis. Circulation 2002;106:2842-7.
23. Soman N, Lanza G, Heuser J, Schlesinger P, Wickline S. Synthesis and characterization of stable fluorocarbon nanostructures as drug delivery vehicles for cytolytic peptides. Nano Lett 2008;8:1131-6.
24. Pan D, Schmieder AH, Wang K, Yang X, Senpan A, Cui G, et al. Antiangiogenesis therapy in the Vx2 rabbit cancer modelwith a lipase-cleavable Sn 2 taxane phospholipid prodrug using alpha (v) beta (3)-targeted theranostic nanoparticles. Theranostics 2014;4:565-78.
25. Zhou HF, Yan H, Senpan A, Wickline SA, Pan D, Lanza GM, et al. Suppression of inflammation in a mouse model of rheumatoid arthritis using targeted lipase-labile fumagillin prodrug nanoparticles. Biomaterials 2012;33:8632-40.
26. Pan D, Sanyal N, Schmieder AH, Senpan A, Kim B, Yang X, et al. Antiangiogenic nanotherapy with lipase-labile Sn-2 fumagillin prodrug. Nanomedicine (Lond) 2012;7:1507-19.
27. Meoli DF, Sadeghi MM, Krassilnikova S, Bourke BN, Giordano FJ, Dione DP, et al. Noninvasive imaging of myocardial angiogenesis following experimental myocardial infarction. J Clin Invest 2004;113:1684-91.
28. Sadeghi MM, Krassilnikova S, Zhang J, Gharaei AA, Fassaei HR, Esmailzadeh L, et al. Detection of injury-induced vascular remodeling by targeting activated alphavbeta3 integrin in vivo. Circulation 2004;110:84-90.
29. Peng L, Liu R, Marik J, Wang X, Takada Y, Lam KS. Combinatorial chemistry identifies high-affinity peptidomimetics against alpha4beta1 integrin for in vivo tumor imaging. Nat Chem Biol 2006;2:381-9.
30. Pan D, Kim B, Hu G, Gupta DS, Senpan A, Yang X, et al. A strategy for combating melanoma with oncogenic c-Myc inhibitors and targeted nanotherapy. Nanomedicine 2015;10:241-51.
31. Gupta DS, Kaul D, Kanwar AJ, Parsad D. Psoriasis: crucial role of LXR-alpha RNomics. Genes Immun 2010;11:37-44.
32. Soodgupta D, Hurchla MA, Jiang M, Zheleznyak A, Weilbaecher KN, Anderson CJ, et al. Very late antigen-4 (alpha (4) beta (1) integrin) targeted PET imaging of multiple myeloma. PloS One 2013;8:e55841.
33. Ferrari M, Fornasiero MC, Isetta AM. Mtt colorimetric assay for testing macrophage cytotoxic activity in vitro. J. Immunol Meth 1990;131:165-72.
34. Zirath H, Frenzel A, Oliynyk G, Segerstrom L, Westermark UK, Larsson K, et al. MYC inhibition induces metabolic changes leading to accumulation of lipid droplets in tumor cells. Proc of the Natl Acad of Sci U S A 2013;110:10258-63.
35. Muller I, Larsson K, Frenzel A, Oliynyk G, Zirath H, Prochownik EV, et al. Targeting of the MYCNprotein with small molecule c-MYC inhibitors. PloS One 2014;9:e97285.
36. Ria R, Vacca A, Ribatti D, Di Raimondo F, Merchionne F, Dammacco F. Alpha (v) beta (3) integrin engagement enhances cell invasiveness in human multiple myeloma. Haematologica 2002;87:836-45.
37. Kiziltepe T, Ashley JD, Stefanick JF, Qi YM, Alves NJ, Handlogten MW, et al. Rationally engineered nanoparticles target multiple myeloma cells, overcome cell-adhesion-mediated drug resistance, and show enhanced efficacy in vivo. Blood Cancer J 2012;2:e64.